Ivermectin + Mebendazole: Groundbreaking Study Reports 84.4% Clinical Benefit Rate in Cancer Patients

Ivermectin + Mebendazole: Groundbreaking Study Reports 84.4% Clinical Benefit Rate in Cancer Patients

A newly released observational analysis found that 84.4% of cancer patients treated off-label with a compounded combination of Ivermectin and Mebendazole experienced a clinical benefit.